China begins new knee OA cell study to evaluate a human adipose-derived mesenchymal precursor cell therapy

By

KNEE OA CELL THERAPY TRIALS IN CHINA (Orthopedics This Week)
Renji Hospital in Shanghai, a tertiary hospital affiliated with Shanghai Jiao Tong University School of Medicine, has given approval for a Phase IIb clinical trial for ReJoin. ReJoin is a human adipose-derived mesenchymal precursor cell therapy bio-engineered for knee osteoarthritis (KOA) by Cellular Biomedicine Group, Inc.
The trial will test the safety and efficacy of intra-articular injections of autologous (patient’s own) ReJoin formula in order to reduce inflammation and repair damaged joint cartilage.
“The approval of our Phase...

Get access to full posts newsletters, trends, and market reports for only subscribe for $1/day.
Hit the SUBSCRIBE button at the top of the homepage.